Natera, Inc. (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 24,861 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 24,861 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $4,101,319.17. Following the completion of the transaction, the insider now directly owns 140,684 shares in the company, valued at $23,208,639.48. The trade was a 15.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, December 9th, Solomon Moshkevich sold 4,858 shares of Natera stock. The shares were sold at an average price of $166.59, for a total value of $809,294.22.
• On Monday, October 28th, Solomon Moshkevich sold 1,196 shares of Natera stock. The stock was sold at an average price of $118.21, for a total value of $141,379.16.

Natera Price Performance

Shares of NTRA stock traded down $4.21 on Friday, reaching $167.61. The company had a trading volume of 909,104 shares, compared to its average volume of 1,393,352. The stock has a market capitalization of $22.13 billion, a PE ratio of -95.23 and a beta of 1.65. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The business’s 50-day moving average is $166.20 and its 200 day moving average is $136.07. Natera, Inc. has a one year low of $62.96 and a one year high of $183.00.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company’s revenue was up 63.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.95) earnings per share. Equities research analysts forecast that Natera, Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on NTRA shares. JPMorgan Chase & Co. raised their price target on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Sanford C. Bernstein lifted their price target on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, January 10th. TD Cowen boosted their price target on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Piper Sandler raised their price objective on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, November 18th. Finally, Guggenheim lifted their price objective on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $162.94.

Hedge Funds Weigh In On Natera

Institutional investors and hedge funds have recently bought and sold shares of the company. Covestor Ltd lifted its holdings in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the period. Blue Trust Inc. lifted its holdings in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after buying an additional 97 shares during the period. GAMMA Investing LLC grew its position in shares of Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares during the last quarter. Hanseatic Management Services Inc. increased its stake in shares of Natera by 12.0% in the fourth quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company’s stock valued at $158,000 after buying an additional 107 shares during the period. Finally, Salem Investment Counselors Inc. raised its position in shares of Natera by 0.7% during the fourth quarter. Salem Investment Counselors Inc. now owns 16,280 shares of the medical research company’s stock worth $2,577,000 after acquiring an additional 110 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.